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MODELING THE IMPACT OF A NEW ORAL 
ANTI-DIABETIC TREATMENT ON DIABETES 
COMPLICATION COSTS IN FRANCE
Brun-Strang C1, Caro J2, Annemans L3, O’Brien J2, Everhard 
F4, Grueger J4
1Novartis Pharma S.A, Rueil-Malmaison, France; 2Caro 
Research Institute, Concord, MA, USA; 3HEDM, Meise, 
Belgium; 4Novartis Pharmaceuticals AG, Basel, Switzerland
OBJECTIVE: A cost-effectiveness analysis was conducted
to compare the long-term clinical and economic benefits of
nateglinide, a new oral antidiabetic drug (OAD), plus met-
formin with metformin plus other OAD and with met-
formin alone in patients with type 2 diabetes whose glyce-
mia is not controlled with metformin monotherapy.
METHODS: The health status of a cohort of 10,000 type
2 diabetic patients at risk of developing microvascular
and macrovascular complications was simulated by a
Markov model, tracking patient evolution over 30 years
in one year periods. The risk of microvascular complica-
tions was based on published longitudinal studies. A
Weibull model predicted the incidence of macrovascular
complications depending on the level of glycemic control
(measured both in terms of HbA1c level and postprandial
glucose) and other patient characteristics. Costs of com-
plications were assessed as event costs covering the acute
and first-year management of the complication and state
costs, which occur in years after the event. The primary
outcome measure was the cost per Life Year Saved (LYS).
The analysis was conducted from a health-care-payer
perspective. Costs were discounted by 5% per year.
RESULTS: Type 2 diabetic patients taking nateglinide
plus metformin would live from 0.11 to 0.39 years more
than patients taking metformin plus OAD or metformin
alone. The total costs over the entire time horizon ranged
from 18,020 Euros for metformin alone to 20,694 Euros
for metformin plus nateglinide. The resulting cost-effec-
tiveness ratios (from 6,234 to 11,360 Euros per LYS)
with nateglinide are well within what is considered as
cost-effective care. In the sensitivity analysis, the impact
of the observed variation was moderate or in favour of
nateglinide plus metformin.
CONCLUSION: Nateglinide in combination with met-
formin is likely to be a cost-effective investment in type 2
diabetic patients inadequately controlled with metformin
alone.
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COST-EFFECTIVENESS OF PIOGLITAZONE 
(ACTOS®, TAKEDA) IN THE MANAGEMENT OF 
TYPE 2 DIABETES MELLITUS IN SWEDEN
Henriksson F1, Brandt A2, Thomander L3, Kielhorn A4, Jansen 
R4, Maniadakis N5
1Stockholm School of Economics, Stockholm, Sweden; 
2Institute for Medical Informatics and Biostatistics (IMIB), 
Riehen, Switzerland; 3Eli Lilly, Stockholm, Sweden; 4Eli Lilly, 
Windlesham, Surrey, UK; 5Eli Lilly, Windlesham Surrey, UK
OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) in combination therapy versus usual care for
patients with type2 diabetes in Sweden.
METHODS: A published, validated model for type 1 dia-
betes mellitus developed by the Institute of Medical In-
formatics and Biostatistics was adapted to simulate long-
term (until death) management, health outcomes, resource
utilisation and treatment costs of patients with type2 dia-
betes. The model accounts for most complications occur-
ring in diabetes patients: nephropathy, retinopathy, acute
myocardial infarction, angina pectoris, stroke and ampu-
tation. The analysis was done from third-party-payer per-
spective and costs figured relative to the year 2000. A 3%
discount rate was applied to costs and outcomes and sen-
sitivity analysis was performed to test the results.
RESULTS: PIO in combination with metformin (MF)
was associated with longer life expectancy (15.6 years)
than sulphonylureas (SU)/MF (14.9) or rosiglitazone
(RSG) 8 mg/MF (15.5). The same applied for PIO 15 mg/SU
(15.5 years) with a greater life expectancy than MF/SU
(15.0) and RSG 4 mg/SU (15.3). Furthermore, PIO 30
mg/MF, PIO 30 mg/SU, PIO 15 mg/SU were associated
with the lowest number of serious complications. For ev-
ery 33 patients treated with PIO 30 mg/MF instead of
SU/MF, one death was avoided. The higher expense of
the PIO combination was offset in some, but not all sce-
narios, by a reduction in incidence of complications. The
incremental undiscounted cost per life year gained of PIO
30 mg/MF relative to SU/MF and RSG 8 mg/MF was re-
spectively 86,440 Sweden Kronor (SEK) and 123,313
SEK. After discounting both costs and life years at 3%,
the above becomes 146,196 SEK and 148,561 SEK, re-
spectively. Finally, after discounting, PIO 15 mg/SU ver-
sus MF/SU or RSG 4 mg/SU was associated with an in-
cremental cost per life year gained of 123,029 SEK and
42,401 SEK, respectively.
CONCLUSION: This model suggests that combined
treatments with pioglitazone improve survival and reduce
complications in patients with type2 diabetes and repre-
sent a cost-effective choice in Sweden when judged
against other therapeutic interventions. Nonetheless, the
results of modelling exercises such as this should be con-
firmed by long-term observational studies.
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THE LIFETIME DIRECT MEDICAL COSTS OF 
MANAGING DIABETES AND ITS 
COMPLICATIONS IN FRANCE
Grueger J1, O’Brien JA2, Caro JJ2, Brun C3, Everhard F1
1Novartis Pharmaceuticals AG, Basel, Switzerland; 2Caro 
Research Institute, Concord, MA, USA; 3Novartis Pharma,
Rueil Malmaison, France
OBJECTIVES: Several studies have assessed the cost of
micro- and macrovascular complications of diabetes. The
objective of this study was to examine the components of
the lifetime costs of diabetes in France.
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METHODS: A published economic simulation model of
diabetes has been modified to allow for the calculation of
the costs of glycemic management and of treating dia-
betic complications over time. Age, gender, racial compo-
sition, cardiovascular risk factors and glycemic parame-
ters were taken from a recent clinical trial in diabetic
patients. The risks of complications were derived from
epidemiological studies. Costs of management of diabetes
and its complications were based on French tariffs, pub-
lished literature, and expert opinion. A cohort of 10,000
diabetic patients was simulated for 30 years. Future costs
were discounted at 5% per year.
RESULTS: On average, the cumulative direct medical
costs of managing diabetes and treating complications ac-
crue to FFR 103,431 (€15,767) per patient. During the
first eight years, more than 50% of the total costs are at-
tributed to the treatment of macrovascular complica-
tions, stroke and myocardial infarction. Over more than
20 years, the cost of microvascular complications will
rise to over 50%, driven primarily by the cost of end-
stage renal disease. The cost of managing diabetes will re-
main at approximately 10% of the total cost throughout
the model period.
CONCLUSIONS: Treatment of macrovascular complica-
tions dominates the total cost of diabetes over the first de-
cade. Only after 20 years or more of treatment do the costs
of microvascular complications become more important.
Thus, the focus should be on efforts to reduce the risks of
stroke and myocardial infarction in these patients.
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A POPULATION STUDY OF HEALTH-CARE 
COSTS ASSOCIATED WITH HYPOGLYCAEMIA
Wang J1, Broomhall J1, Leese G2, Morrison B2, Morris A1, 
Davey P3
1MEMO, University of Dundee, Dundee, UK; 2Tayside 
University Hospitals Trust, Dundee, UK; 3MEMO, University of 
Dundee, Dundee, Scotland, UK
OBJECTIVE: To quantify use of health-care resources
for management of severe hypoglycaemia.
METHODS: We defined severe hypoglycaemia as an epi-
sode of coma or seizure requiring assistance from NHS
personnel. We excluded any episodes managed exclu-
sively by persons outside the health services. We included
all patients with Type 1 or Type 2 diabetes registered
with DARTS (Diabetes Audit and Research in Tayside
Scotland) and receiving treatment with insulin or oral hy-
poglycaemic drugs from June 1, 1997 to May 31, 1998.
We identified episodes from the records of three acute-
care hospital emergency rooms, eight minor injury units
in primary-care hospitals and from Tayside Ambulance
Service records.
RESULTS: Over 150,000 records were searched to iden-
tify 295 people with one or more episodes, of which 39
were excluded because they were not residents of Tayside
and another 12 because their identity could not be reli-
ably confirmed. The incidence of major hypoglycaemia
per 100 patient years was 12.0 (95% CI 8.2-13.7) in
Type 1 diabetics, 6.8 (CI 5.2-8.9) in Type 2 diabetics tak-
ing insulin and 0.8 (CI 0.6-1.0) in Type 2 diabetics on
oral hypoglycaemics. Fifty-two patients required inpa-
tient treatment. This compares with an incidence of 2.3
per 100 patient years for patients treated with insulin in
the UKPDS trial and 5.4 in the conventional arm of the
DCCT trial. The total health-care costs were £115,541 of
which 64% was for inpatient stay, 25% for ambulance
and 11% for emergency room.
CONCLUSIONS: The incidence of hypoglycaemia was
three- to five-fold higher than previously reported in clin-
ical trials, and extrapolation of our costs suggests that
hypoglycaemia could cost the UK NHS as much as
£16.2m per year.
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THE EVENT AND STATE COST OF 
COMPLICATIONS OF DIABETES IN THE 
NETHERLANDS
Koopmanschap MA1, van den Boom G2, O’Brien J3, 
Grueger J4
1Erasmus University, Rotterdam, Netherlands; 2Novartis 
Pharma, Arnhem, Netherlands; 3Caro Research, Concord, MA, 
USA; 4Novartis Pharmaceuticals AG, Basel, Switzerland
OBJECTIVE: Prospective studies like UKPDS have
shown that improved glycemic control in diabetic pa-
tients can reduce the risk of micro- and macrovascular
complications. To estimate the potential savings to health-
care systems due to interventions aimed at improving gly-
cemic control, the cost of complications must be known.
The objective of this study was to assess the cost of com-
plications in type 2 diabetic patients in the Netherlands.
METHODS: A review of published literature and guide-
lines was combined with data from ongoing research
projects and expert interviews to define the management
patterns for diabetic complications. Data from detailed
cost studies were used to estimate the Event cost (i.e.,
acute and post-acute care cost in the first year) and State
cost (i.e., subsequent recurring annual cost) of complica-
tions in 2000 NLG.
RESULTS: The cost of nephropathy was dominated by
the State cost of end stage renal disease (NLG 132,692).
Event and State costs due to retinopathy were relatively
low, except for the State cost of blindness (NLG 5,000).
Lower extremity amputation costs NLG 33,683 per event
and NLG 1,148 per year for subsequent management.
The event cost for AMI and stroke were NLG 21,877
and NLG 39,867, respectively. The subsequent State
costs were estimated at NLG 4,286 and NLG 16,131.
Over a simulated 30-year time horizon, the cost due to
macrovascular complications would account for 46% of
the total cost of complications discounted at 4%.
CONCLUSION: The cost of diabetic complications in
the Netherlands is substantial. Interventions that improve
glycemic control, and moreover, that affect the incidence
